Research ExplorerPublicationsWorldwide Network for Blood and Marrow Transplantation (WBMT...

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

Standard

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. / Muhsen, Ibrahim N; Hashmi, Shahrukh K; Niederwieser, Dietger; Kroeger, Nicolaus; Agrawal, Samir; Pasquini, Marcelo C; Atsuta, Yoshiko; Ballen, Karen K; Seber, Adriana; Saber, Wael; Kharfan-Dabaja, Mohamed A; Rasheed, Walid; Okamoto, Shinichiro; Khera, Nandita; Wood, William A; Koh, Mickey B C; Greinix, Hildegard; Kodera, Yoshihisa; Szer, Jeff; Horowitz, Mary M; Weisdorf, Daniel; Aljurf, Mahmoud.

In: BONE MARROW TRANSPL, Vol. 55, No. 4, 04.2020, p. 698-707.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Muhsen, IN, Hashmi, SK, Niederwieser, D, Kroeger, N, Agrawal, S, Pasquini, MC, Atsuta, Y, Ballen, KK, Seber, A, Saber, W, Kharfan-Dabaja, MA, Rasheed, W, Okamoto, S, Khera, N, Wood, WA, Koh, MBC, Greinix, H, Kodera, Y, Szer, J, Horowitz, MM, Weisdorf, D & Aljurf, M 2020, 'Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries', BONE MARROW TRANSPL, vol. 55, no. 4, pp. 698-707. https://doi.org/10.1038/s41409-019-0658-2

APA

Muhsen, I. N., Hashmi, S. K., Niederwieser, D., Kroeger, N., Agrawal, S., Pasquini, M. C., Atsuta, Y., Ballen, K. K., Seber, A., Saber, W., Kharfan-Dabaja, M. A., Rasheed, W., Okamoto, S., Khera, N., Wood, W. A., Koh, M. B. C., Greinix, H., Kodera, Y., Szer, J., ... Aljurf, M. (2020). Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. BONE MARROW TRANSPL, 55(4), 698-707. https://doi.org/10.1038/s41409-019-0658-2

Vancouver

Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. BONE MARROW TRANSPL. 2020 Apr;55(4):698-707. https://doi.org/10.1038/s41409-019-0658-2

Bibtex

@article{bd8f68d55a9444eaa5dba3146b67920d,
title = "Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries",
abstract = "Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.",
author = "Muhsen, {Ibrahim N} and Hashmi, {Shahrukh K} and Dietger Niederwieser and Nicolaus Kroeger and Samir Agrawal and Pasquini, {Marcelo C} and Yoshiko Atsuta and Ballen, {Karen K} and Adriana Seber and Wael Saber and Kharfan-Dabaja, {Mohamed A} and Walid Rasheed and Shinichiro Okamoto and Nandita Khera and Wood, {William A} and Koh, {Mickey B C} and Hildegard Greinix and Yoshihisa Kodera and Jeff Szer and Horowitz, {Mary M} and Daniel Weisdorf and Mahmoud Aljurf",
year = "2020",
month = apr,
doi = "10.1038/s41409-019-0658-2",
language = "English",
volume = "55",
pages = "698--707",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

AU - Muhsen, Ibrahim N

AU - Hashmi, Shahrukh K

AU - Niederwieser, Dietger

AU - Kroeger, Nicolaus

AU - Agrawal, Samir

AU - Pasquini, Marcelo C

AU - Atsuta, Yoshiko

AU - Ballen, Karen K

AU - Seber, Adriana

AU - Saber, Wael

AU - Kharfan-Dabaja, Mohamed A

AU - Rasheed, Walid

AU - Okamoto, Shinichiro

AU - Khera, Nandita

AU - Wood, William A

AU - Koh, Mickey B C

AU - Greinix, Hildegard

AU - Kodera, Yoshihisa

AU - Szer, Jeff

AU - Horowitz, Mary M

AU - Weisdorf, Daniel

AU - Aljurf, Mahmoud

PY - 2020/4

Y1 - 2020/4

N2 - Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

AB - Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

U2 - 10.1038/s41409-019-0658-2

DO - 10.1038/s41409-019-0658-2

M3 - SCORING: Review article

C2 - 31484992

VL - 55

SP - 698

EP - 707

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 4

ER -